Phase-controlled rescanning of the carbon-ion beam offers fast and precise dose application with decreased irradiation of normal tissue. However, organ movement with respiration remains a unique challenge. Technological development has enabled the simultaneous application of beamenergy-modulated markerless phase-controlled rescanning with respiration gating, allowing scanning treatment of respiration-mobile tumors with carbon. A total of 10 patients with tumors in the liver or lung were treated in a feasibility study at our facility using this combination. At a median of 10.5 months, follow-up examination including computed tomography/magnetic resonance imaging revealed no grade 2+ acute adverse effects with this new therapy. Two patients with complex disease experienced local recurrence, which may be improved with increased dose delivery. One patient died of unrelated causes. All other patients are alive with good control at the time of writing. Though long-term observation is pending, these are promising initial results for use of the carbon-beam phase-controlled rescanning method in respiration-mobile disease.
Introduction
Radiotherapy hinges on delivering maximal dose to disease while minimizing irradiation of healthy tissue. In comparison with photon treatment, which is largely continuous throughout a target, particle therapy allows dose focusing at a single point with minimal entry and effectively no exit dose. Particle therapy today primarily consists of proton and carbon-ion irradiation; the high relative biological efficacy (RBE) of carbon ions coupled with its high dose homogeneity make it a powerful tool in the treatment of cancer (1, 2) .
The passive scattering irradiation method was employed for 20 years at the National Institute of Radiological Sciences (NIRS), Japan, utilizing scatterers, collimators and compensators to fit the carbon-ion beam to the target. The patient-and target-specific collimators and compensators contribute to treatment cost, and require storage post-treatment due to radioactivity. Further, the scattering method yields excess dose proximal to the disease site, and neutrons generated by interaction with the scatterer can increase the integral dose delivered to a patient. However, the method is forgiving of organ motion with respiration, owing to dose 'smearing' inherent to the scattering process. Regardless, a more conformal treatment to target tissue was desired.
The Gesellschaft fur Schwerionenforschung (GSI) center in Germany pioneered carbon-ion raster pencil-beam scanning (PBS), treating patients for the first time in 1997. The PBS method directs a thin, unscattered beam to individual target points in sequence (3), with beam depth controlled either solely by energy modulation or by using a range-shifter (hybrid energy system). The beam direction is repositioned using horizontal and vertical magnets. The removal of scatterers reduces costs, while the method allows for targeted pinpoint accuracy without the excess proximal dose seen with the passive method. The accuracy of PBS comes with a price: the method is sensitive to tumor motion.
In 2011, clinical trials were completed at NIRS using the PBS method, demonstrating improved dose distribution and reinforcing the results of international centers (4, 5) . Initial usage was limited to static sites, as development to compensate for respiratory motion and consequential interplay effects continued (6, 7) . The phasecontrolled rescanning (PCR) method followed, consisting of rapid irradiation of each point in a target eight or more times in a treatment course, and enabling scanning-beam treatment of disease with significant intrafractional target movement (4, 8, 9) . Owing to the more manageable treatment times created by the increased speed of the PCR method, regular implementation of respiratory gating became possible (8, 10) . Over the course of development, a four-dimensional computed tomography (CT) treatment planning tool (4Dtool (11)) as well as a markerless tumor-tracking X-ray fluoroscopic imaging system were constructed (12) . The combined system has been experimentally verified in simulation studies (4, 11, 13, 14) , including for hepatocellular carcinoma (HCC) (9) . Prospective evaluation of gated positional accuracy for a clinical trial of markerless respiratory-gated carbon PBS treatment was also performed (15) .
In March 2015, a feasibility-oriented clinical trial began to evaluate this combined system in the treatment of cancers in the lung and liver. Here we report our initial impressions.
Methods

Patient selection and eligibility
This was a prospective feasibility study to evaluate the safety of the combined layered PCR-CIRT method with respiratory gating. Three patients with chest and three with abdominal disease were set as minimum, with a maximum total of 12. Enrollment was based on the following inclusion criteria: (1) lesion location in the chest or abdomen, (2) lesion can be treated by passive carbon-ion radiotherapy (CIRT), (3) lesion requires respiratory gating to deliver CIRT, (4) no heart or kidney failure, (5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, (6) inoperable for medical reasons or surgically unresectable, (7) no apparent signs of interstitial pneumonitis or refractory infection on CT, (8) no history of radiotherapy local to the lesion, (9) prognosis of more than 6 months of life and (10) patient was able to competently understand the research and of independent volition consent to the trial. Informed written consent for the trial and follow-up study was obtained from all patients prior treatment. The study was approved by the NIRS ethics committee.
Initial 
Radiotherapy technique
Dose was expressed in photon-equivalent doses (Gy(RBE)), derived by multiplication of physical dose by the RBE of carbon ions (16) . Carbon-ion beams generated by the Heavy-Ion Medical Accelerator in Chiba (HIMAC) were used to deliver external CIRT using the hybrid-depth scanning technique with markerless amplitude-based respiratory gating, as previously described (15) . Patients were immobilized using an individually tailored device (Moldcare by Alcare, Tokyo, Japan; Shellfitter by Kuraray, Osaka, Japan), fixed in the prone or supine position with hands over their head. Four-dimensional computed tomography (4DCT) data were obtained using a 320-detector CT (Aquilion One Vision, Toshiba Medical Systems, Japan) under free-breathing conditions with monitoring by a respiratory sensing system (Toyonaka Kenkyujo, Osaka, Japan). As beam ports are fixed horizontally and vertically, patients were rotated laterally as needed to a limit of +/-20°, so as to minimize incidental exposure to sensitive normal tissues. Targets were delineated at maximum-exhalation (T50) by radiation oncologists, with registration errors evaluated as described previously (9) . The primary tumor was contoured as gross tumor volume (GTV) manually, with clinical target volume (CTV) derived at T50 from reference data. Planning target volume setup margins and CTV expansion were calculated so as to expand beam 'on'-time (15) .
Prescribed dose was identical to what would be delivered with the passive method, based on previous institutional experience and prior clinical trials. Irradiation was performed with respiration gating (T30-T70) using the layered PCR scanning method with eight or more rescannings, with the same spot size and spacing used in all iso-energy layers. A treatment plan can be seen in Fig. 1 .
Follow-up
Following therapy, regular follow-up examinations have been and will be performed at 3 months for the first 2 years, and then every 
Endpoint/analyses
The primary endpoint, toxicity in response to the treatment method, was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, with the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria used as supplement. Outcomes were summarized using standard descriptive analysis.
Results
Patient characteristics
Ten patients were identified and enrolled in the trial ( 
Adverse effects/toxicity
No Grade 2 or higher acute toxicity was seen in any patient. Eight patients experienced a Grade 1 skin reaction at 3 months (nine at 6 months), and eight patients experienced a Grade 1 lung reaction at 3 months (nine at 6 months). One patient experienced a Grade 1 liver response, measured as an alanine transferase increase (Table 1) Control and survival
Two patients with complex disease, anal cancer metastasis to the lung and retroperitoneal liposarcoma metastasis to the liver, experienced recurrence at 10.7 and 9.7 months, respectively. One patient died of causes unrelated to disease treatment at 11.5 months. Three patients with disease treated in the liver (2 HCC, 1 HCC/cholangiocarcinoma mix) experienced regional progression.
Discussion
Our previous experiences with the scanning method on static tumors at our institution have been favorable, with over 1000 patients treated to date. In comparison with the passive method, no significant differences have been noted in terms of adverse or therapeutic effects. The ability to couple layered PCR with respiration gating, allowing treatment of respiration-mobile tumors, in theory enables the dose distributive benefits of the scanning method to be extended to disease in all locations of the body. The initial follow-up in our study has demonstrated minimal adverse effects from treatment, appearing approximately equal to those adverse effect profiles seen with the passive treatment method. It is possible that the minimization of proximal dose, as well as improved dose targeting and dose distribution afforded by the scanning method, has contributed to the lack thus far of grade 2 or higher adverse effects. Nonetheless, at 6 months 9 of 10 patients experienced grade 1 reactions. With further experience, adverse effects may yet be reduced.
Our results build off passive-method protocols, including hypofractionation of treatment to 2 fractions for HCC. This preliminarily suggests that protocols developed with the passive method may serve as starting points for scanning-beam protocols. Of note, two patients with particularly complex, radioresistant disease experienced local progression. Both cases, one an anal cancer metastasis and the other a large retroperitoneal liposarcoma, would be difficult to treat with the passive beam; the outcomes seen here do not differ greatly from what may otherwise be expected, and yielded 10.7 and 9.7 months of locally controlled disease, respectively. The improved dose distribution of the scanning method may enable delivery of higher treatment dose than the passive method, further improving local control of complex disease. Further study is warranted.
The outcomes seen here mirror those of our colleagues at the Heidelberg Ion-Beam Therapy Center (HIT), who previously published on carbon-ion rasterscanning in respiration-mobile disease (5) . In their feasibility study, published in 2013, six HCC patients with seven lesions were treated with carbon-ion beams using the scanning-beam method, delivered in 4 fractions of 10 Gy (RBE). They employed abdominal compression, respiration gating in one Figure 1 . Carbon-ion radiotherapy treatment plan for disease in the liver. Liver cysts can also be seen.
patient, and 4D treatment reconstruction, with concern noted regarding interplay effects. Partial response and stable disease were subsequently seen in 4 and 3 of 7 lesions, respectively, with 100% local control and no severe adverse effects reported. Their efforts continue in the PROMETHEUS-01 trial (NCT01167374). At the time of writing, no reports regarding the scanning method and lung disease were found in the literature, though plans at HIT include a clinical trial on lung cancer patients with chest wall infiltration (17) .
Conclusions
Our early results suggest that the PCR method of CIRT can be safely combined with respiration gating for treatment of mobile tumors. This is the first trial to demonstrate such on multiple targets within the chest and abdomen. This combination method appears compatible with previous data generated with the passive beam, and moreover allows treatment without abdominal compression, improving patient comfort. Follow-up to evaluate any long-term adverse effects, as well as longitudinal study to evaluate overall method benefits and outcomes versus the established passive treatment method, are needed. We are optimistic that further studies will demonstrate an improvement in adverse effects in comparison with passive irradiation, with equal or better control and survival outcomes. Future developments, including further implementation of intensity-modulated particle therapy, linear energy transfer dose painting, and improving treatment beam angles through use of gantries, may further improve results.
